BIO-tract tablets protect probiotics from damaging stomach acids, releasing live organisms over time to the upper and lower intestinal tracts.
Nutraceutix Inc. (Redmond, WA) has obtained a U.S. patent (No. 8,007,777; “Delivery System for Biological Component”) for its BIO-tract probiotic technology. The company has four other international patents for BIO-tract, in China, Australia, Russia, and Singapore, with other patents pending.
Unlike powders, capsules, and cultured foods, BIO-tract tablets protect probiotics from damaging stomach acids, releasing live organisms over time to the upper and lower intestinal tracts, the company says. BIO-tract also benefits from Nutraceutix’s LiveBac process, which is said to extend probiotic shelf life beyond other supplement forms, even at room temperature.
“BIO-tract caplets with LiveBac processing are unparalleled when it comes to the effective delivery of live probiotic organisms to the body,” stated Tim Gamble, Nutraceutix’s president and CEO, in a press release.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.